NDRA · ENDRA Life Sciences Inc.
$4.60
+0.03 (+0.55%)
At close · Aug 7
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company has not established an ongoing source of revenue sufficient to cover its operating costs and to allow it to continue as a going concern and will require additional financing to fund its future planned operations, including research and development and commercialization of its products. These matters raise substantial doubt about the Company's ability to continue as going concern.”View the 10-Q filed May 15, 2026
Market Cap
$5.84M
Shares
1.27M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
FY2020
Net Income
-$7.03M
+38.9%
FY2025
Gross Margin
100%
+49.1pp
FY2018
Operating Margin
-146080.47%
-144764.8pp
FY2018
Diluted EPS
-$8.93
+84.3%
FY2025
Operating Cash Flow
-$5.18M
+30%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | $0 | $0 | $6174 | $351.62K | |
| — | — | — | — | — | — | $0 | $0 | $0 | — | |
| — | — | — | — | — | — | $0 | $0 | $6174 | $178.84K | |
| — | — | — | — | — | — | — | — | 100% | 50.86% | |
| $2.1M | $1.85M | $3.19M | $5M | $6.55M | $5.48M | $5.92M | $6.57M | $4.72M | $1.93M | |
| $124.76K | $189.47K | $571.04K | $820.55K | $1.43M | $1.08M | $581.89K | $412.43K | $262.64K | $122.6K | |
| $4.25M | $3.72M | $7.06M | $4.7M | $5.17M | $4.94M | $5M | $3.86M | $3.75M | $2.75M | |
| — | $44.05K | $46.49K | $123.73K | $96.66K | $116.24K | $99.34K | $80.58K | $68.32K | $61.48K | |
| $6.47M | $5.76M | $10.82M | $10.52M | $13.16M | $11.5M | $11.5M | $10.84M | $9.03M | $4.8M | |
| -$6.47M | -$5.76M | -$10.82M | -$10.52M | -$13.16M | -$11.5M | -$11.5M | -$10.84M | -$9.02M | -$4.63M | |
| — | — | — | — | — | — | — | — | -146080.47% | -1315.63% | |
| — | -$5.72M | -$10.77M | -$10.4M | -$13.06M | -$11.38M | -$11.4M | -$10.76M | -$8.95M | -$4.56M | |
| — | — | — | — | — | — | — | — | — | $42.63K | |
| -$834.95K | -$1.26M | -$690.8K | $460.49K | -$21.53K | $267.06K | -$223.58K | -$2.46M | -$777.25K | — | |
| -$7.3M | -$7.03M | -$11.51M | -$10.06M | -$13.18M | -$11.23M | -$11.73M | -$13.31M | -$9.8M | -$5.38M | |
| $0 | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| -$7.3M | -$7.03M | -$11.51M | -$10.06M | -$13.18M | -$11.23M | -$11.73M | -$13.31M | -$9.8M | -$5.38M | |
| — | — | — | — | — | — | — | — | -158669.6% | -1529.19% | |
| — | — | — | — | -$13.18M | -$11.35M | -$12.12M | -$17.53M | — | — | |
| USD/shares | — | -$8.93 | — | — | -$7,980.00 | -$9,800.00 | — | — | — | — |
| USD/shares | — | -$8.93 | -$56.94 | — | — | — | — | — | — | — |
| shares | — | 787.02K | — | — | — | — | 548.3493 | 214.2853 | 128.7107 | 78.7702 |
| shares | — | 787.02K | 202.11K | — | — | — | 548.3493 | 214.2853 | 128.7107 | 78.7702 |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Diagnostics & Research median 3.22×
EV/EBIT
—
Diagnostics & Research median 31.86×
P/E (TTM)
—
Diagnostics & Research median 32.66×
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| CODM | -$5,763,101 | -$10,817,147 |